We searched Medline with the terms “rheumatoid arthritis” and “diagnosis”, “pathology”, “pathogenesis”, and “treatment”, and other specific terms when needed, and included all reports published between March, 1968, and March, 2008. We reviewed abstracts and selected relevant papers. All types of articles were included (original work, review, case report, letter, etc). We tried to select the most recent publications and to refer to the original description (that means first publication on
SeminarRheumatoid arthritis
Introduction
Rheumatoid arthritis is a disorder in rapid transition. It has evolved from a syndrome of unknown cause to one for which distinct subsets of disease are emerging, and growing knowledge of risk factors calls for preventive strategies. Instead of being regarded as a disease of uncertain pathogenesis, rheumatoid arthritis has become a prototype for application of knowledge of molecular pathogenesis for development of new treatments. Previously, resources were used mainly for care and rehabilitation of accrued handicaps; now the disorder has become a modern-day medical dilemma, whereby early treatment can prevent disability in many patients but the most effective new drugs can be too expensive to administer to all people who might benefit. In this Seminar, we describe some of these developments and their results, which, we believe, extend beyond care and cure for the patient with rheumatoid arthritis.
Section snippets
Clinical expression and sub-classification
From Garrod's initial definition of rheumatoid arthritis as a disease in 1859, current classification criteria were developed by American rheumatologists in the mid 1980s (panel).1 These criteria, which have served so well in selecting patients for clinical trials, are now becoming less relevant, partly because of the success of these same trials. At least two of the seven criteria (nodules and erosions) are generally not present at the best time for early diagnosis and initiation of treatment (
Cause and pathogenesis
Rheumatoid arthritis is called a complex genetic disease, meaning that several genes, environmental factors, and stochastic (chance) factors act in concert to cause pathological events. Findings of twin studies have estimated the relative contribution of genetic factors to be about 50% for the entire syndrome of rheumatoid arthritis, leaving the remaining part to environment and chance.9 In an elegant twin study published more than 10 years ago, the power of a causal approach was shown, whereby
Joint inflammation
The causal factors described above emphasise differences between two major subsets of rheumatoid arthritis and suggest a role for adaptive immunity in the initiation of at least ACPA-positive disease. However, findings of direct studies of inflammation in the joints have, for a long time, shown how a series of inflammatory cascades are active, in many cases probably triggered by adaptive immunity. Current data also indicate that similar inflammatory mechanisms could be at work, both in patients
Outcomes
Fatigue—defined as low energy and constant tiredness—was some years ago assumed to be part of a so-called rheumatoid arthritis personality. We now know that fatigue is a physiological state caused by direct action of proinflammatory cytokines—in particular interleukins 6 and 1—on cytokine receptors on brain endothelial cells, which in turn use prostaglandin signalling pathways to affect central parts of the brain.72 Fatigue is, thus, a state that can and should be measured as part of a
Disease progression and treatment
A major key to advances in both assessment and best use of disease-modifying anti-rheumatic drugs (DMARDs) has been development of valid and responsive methods that measure disease activity, functional status, and joint damage. Effects of treatment on disease activity can be measured either as relative improvement or in terms of the absolute value of disease activity that is reached. ACR response criteria89 measure relative changes, whereas the disease activity score (DAS) is a compound index
Treatment strategies
Strategies for treatment of rheumatoid arthritis have changed greatly over the past decade. Three ideas have driven the alteration. First, early and consistent reduction of inflammation is key—ie, if no inflammation, there is little joint damage. Second, specific molecular mechanisms implicated in pathogenesis of the disorder should be targeted. Third, rheumatoid arthritis is a diverse and dynamic disease, for which different treatments work for individual patients and at various timepoints.
Concluding remarks
Despite making major progress in rheumatoid arthritis research, important work still lies ahead of us. Already, new insights into the various molecular pathways have been used to develop new and very efficient treatment approaches for patients. However, we still need to find out how to best target these drugs to the right individuals at the right time. Some environmental risk factors for rheumatoid arthritis have been identified—mainly smoking—but we have not used this knowledge enough in
Search strategy and selection criteria
References (135)
- et al.
Comorbidities in rheumatoid arthritis
Best Pract Res Clin Rheumatol
(2007) - et al.
Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4
Am J Hum Genet
(2005) - et al.
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis
Am J Hum Genet
(2004) - et al.
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis
Am J Hum Genet
(2007) - et al.
Oral contraceptives, cigarette smoking and other factors in relation to arthritis
Contraception
(1987) - et al.
Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis
Lancet
(1989) - et al.
Is IL-1 a good therapeutic target in the treatment of arthritis?
Best Pract Res Clin Rheumatol
(2006) - et al.
Activated T lymphocytes support osteoclast formation in vitro
Biochem Biophys Res Commun
(1999) - et al.
TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis
Am J Pathol
(2001) - et al.
Conventional x-ray in early arthritis
Rheum Dis Clin North Am
(2005)
Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis
Lancet
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial
Lancet
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
Arthritis Rheum
Rheumatoid vasculitis: becoming extinct?
Rheumatology (Oxford)
Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland
Clin Rheumatol
Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort
Arthritis Rheum
Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis: diagnostic value, associations with radiological progression rate, and extra-articular manifestations
Ann Rheum Dis
Use and significance of anti-CCP autoantibodies in rheumatoid arthritis
Rheumatology (Oxford)
Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies
J Clin Invest
Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins
Arthritis Rheum
Cigarette smoking increases the risk of rheumatoid arthritis: results from a nationwide study of disease-discordant twins
Arthritis Rheum
Perinatal characteristics and risk of rheumatoid arthritis
BMJ
Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study
Arthritis Rheum
Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development
Proc Natl Acad Sci USA
Mixed lymphocyte cultures in rheumatoid arthritis
J Clin Invest
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
Nature
TRAF1-C5 as a risk locus for rheumatoid arthritis: a genomewide study
N Engl J Med
The PTPN22 R620W polymorphism associates with RF positive rheumatoid arthritis in a dose-dependent manner but not with HLA-SE status
Genes Immun
A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis
PLoS Med
Two independent alleles at 6q23 associated with risk of rheumatoid arthritis
Nat Genet
STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus
N Engl J Med
Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus
Mol Med
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis
Arthritis Rheum
Association of arthritis with a gene complex encoding C-type lectin-like receptors
Arthritis Rheum
Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis
Arthritis Rheum
Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis
Nat Genet
An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility
Arthritis Rheum
Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England
Arthritis Rheum
A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis
Arthritis Rheum
A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination
Arthritis Rheum
Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles
Ann Rheum Dis
Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark
Arthritis Rheum
Association between occupational exposure to mineral oil and rheumatoid arthritis: results from the Swedish EIRA case-control study
Arthritis Res Ther
Alcohol, androgens and arthritis
Ann Rheum Dis
Ethanol prevents development of destructive arthritis
Proc Natl Acad Sci USA
Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides
Arthritis Res Ther
Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies
Ann Rheum Dis
The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis
Arthritis Rheum
Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis
Proc Natl Acad Sci USA
Cited by (770)
Exploring the efficacy and mechanism of Glycyrrhizae Radix et Rhizoma in improving collagen-induced arthritis in mice
2024, Journal of EthnopharmacologyHuangqi Guizhi Wuwu Decoction suppresses inflammation and bone destruction in collagen-induced arthritis mice
2024, Chinese Herbal MedicinesThe lung as a target and as an initiator of rheumatoid arthritis-associated immunity: Implications for interstitial lung disease
2024, Revista Colombiana de ReumatologiaPathogenic Th17 cells in autoimmunity with regard to rheumatoid arthritis
2023, Pathology Research and PracticePhillyrin ameliorated collagen-induced arthritis through inhibition of NF-κB and MAPKs pathways in fibroblast-like synoviocytes
2023, Arabian Journal of Chemistry